Edwards Lifesciences Corporation (EW)

Over the past six months, Edwards Lifesciences' stock price has fluctuated, decreasing by 6.3% from $85.26 on January 1, 2026, to $79.8580 on May 8, 2026. Key events include reporting Q4 2025 earnings and 2026 guidance in February 2026, securing FDA approval for the SAPIEN M3 mitral valve replacement system in December 2025, and reporting strong Q1 2026 earnings in April 2026. Theodora Mistras was appointed as the new CFO in May 2026. There were reports of possible bearish signals with insiders disposing of stock in May 2026. Ten-year pivotal data from the COMMENCE trial demonstrated the long-term durability of Edwards' RESILIA tissue in surgical aortic valves in May 2026.

The provided search results do not explicitly detail demand seasonality for Edwards Lifesciences' products and services. Demand is generally driven by the prevalence of cardiovascular diseases and the need for medical interventions, rather than typical seasonal consumer patterns. The company's Q1 2026 results showed continued strong commercial execution and sustained physician demand, suggesting a relatively consistent demand driven by medical necessity and clinical adoption rather than strong seasonal fluctuations.

Edwards Lifesciences Corp. is an American medical technology company focused on patient-centered innovations for structural heart disease and critical care monitoring. Founded in 1958 and headquartered in Irvine, California, it operates in the Health Technology sector, specializing in medical instruments and devices. The company focuses on Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care. Edwards Lifesciences sold its Critical Care product group to BD for $4.2 billion in September 2024, planning to use the proceeds for strategic initiatives.

Edwards Lifesciences has a global presence with its headquarters in Irvine, California. It operates major manufacturing facilities in the U.S., Costa Rica, the Dominican Republic, Puerto Rico, and Singapore, with a new facility in Limerick, Ireland, completed in 2021. The company's reporting segments include the U.S., Europe, Japan, and the Rest of the World, with regional offices including one in Washington, D.C., and Edwards Lifesciences (Canada) Inc. in Mississauga, Ontario.

Edwards Lifesciences maintains a strong brand reputation through patient-focused medical innovations and partnerships with clinicians. The company has been recognized on several 'Best Employers' lists by Forbes in 2025 and 2026. Its reputation has been positively impacted by strong financial performance and strategic focus, clinical trial successes, long-term durability data, and strong Q1 2026 performance. No significant negative events impacting its brand reputation in the past year were prominently found in the search results.

Edwards Lifesciences is primarily owned by institutional investors, who held approximately 89% of the shares as of July 24, 2025. Major institutional owners include The Vanguard Group, Inc., BlackRock, Inc., State Street Corp, Wellington Management Company, J.P. Morgan Asset Management, Jennison Associates, Fidelity Management & Research, and Geode Capital Management. Individual investors hold a minority stake, and insiders held 0.34% of the shares as of May 2025.